Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$22.52 - $71.71
Next Earnings Date
May 06 2025
Next Earnings Date
May 06 2025
Latest price
Market Cap | $1.87B |
EV | $866.76M |
Shares Outstanding | 64.38M |
Beta | 3.26 |
Analyst Rating | BUY |
Analyst Target Price | $85.33 |
P/E 2025E | - |
P/Revenue 2025E | 247.02x |
Revenue | 42.80% |
EPS | 2.70% |
Operating Cash Flow | -37.20% |
Free Cash Flow | -75.20% |
Revenue | -4.20% |
EPS | -34.60% |
Operating Cash Flow | -22.00% |
Free Cash Flow | -47.10% |
Gross Margin 2025E | - |
Net Profit Margin 2025E | -4203.26% |
ROE 2025E | -8.29% |
ROCE 2024 | -10.09% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Janux Therapeutics, Inc.
JANX
Sector
Healthcare
Industry
Biotechnology
CEO
Campbell, David
Employees
81
Website
www.januxrx.comIPO Date
2021-06-11
Headquarters
10955 Vista Sorrento Parkway, Suite 200, San Diego, California, 92130, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved